全文获取类型
收费全文 | 2873篇 |
免费 | 187篇 |
国内免费 | 6篇 |
专业分类
耳鼻咽喉 | 16篇 |
儿科学 | 45篇 |
妇产科学 | 24篇 |
基础医学 | 286篇 |
口腔科学 | 57篇 |
临床医学 | 173篇 |
内科学 | 844篇 |
皮肤病学 | 26篇 |
神经病学 | 261篇 |
特种医学 | 227篇 |
外科学 | 519篇 |
综合类 | 20篇 |
预防医学 | 86篇 |
眼科学 | 63篇 |
药学 | 95篇 |
中国医学 | 4篇 |
肿瘤学 | 320篇 |
出版年
2023年 | 31篇 |
2022年 | 46篇 |
2021年 | 102篇 |
2020年 | 72篇 |
2019年 | 74篇 |
2018年 | 102篇 |
2017年 | 71篇 |
2016年 | 70篇 |
2015年 | 93篇 |
2014年 | 110篇 |
2013年 | 116篇 |
2012年 | 211篇 |
2011年 | 212篇 |
2010年 | 106篇 |
2009年 | 101篇 |
2008年 | 145篇 |
2007年 | 161篇 |
2006年 | 154篇 |
2005年 | 164篇 |
2004年 | 165篇 |
2003年 | 147篇 |
2002年 | 151篇 |
2001年 | 44篇 |
2000年 | 42篇 |
1999年 | 42篇 |
1998年 | 34篇 |
1997年 | 18篇 |
1996年 | 31篇 |
1995年 | 18篇 |
1994年 | 13篇 |
1993年 | 19篇 |
1992年 | 31篇 |
1991年 | 25篇 |
1990年 | 12篇 |
1989年 | 18篇 |
1988年 | 17篇 |
1987年 | 14篇 |
1986年 | 14篇 |
1984年 | 6篇 |
1983年 | 4篇 |
1982年 | 5篇 |
1981年 | 4篇 |
1980年 | 7篇 |
1978年 | 7篇 |
1977年 | 5篇 |
1976年 | 5篇 |
1975年 | 5篇 |
1968年 | 3篇 |
1967年 | 2篇 |
1965年 | 2篇 |
排序方式: 共有3066条查询结果,搜索用时 156 毫秒
31.
Hironobu Shibata Masahiro Abe Kenji Hiura Javier Wilde Keiji Moriyama Toshiaki Sano Ken-Ichi Kitazoe Toshihiro Hashimoto Shuji Ozaki Shingo Wakatsuki Shinsuke Kido Daisuke Inoue Toshio Matsumoto 《Clinical cancer research》2005,11(17):6109-6115
PURPOSE: Receptor activator of nuclear factor-kappaB ligand (RANKL) is a key mediator of osteoclastogenesis. Because certain types of tumor cells aberrantly express RANKL, and because bone destruction also develops in B-cell lymphomas of bone origin, we investigated RANKL expression and the mechanisms of osteoclastogenesis in B-lymphoid neoplasms. EXPERIMENTAL DESIGN AND RESULTS: Immunohistochemistry of bone specimens resected from patients with primary B-cell lymphoma of bone with bone destruction revealed that lymphoma cells express RANKL as well as vascular endothelial cell growth factor (VEGF). The tumor cells isolated from the bone specimens enhanced osteoclastogenesis in vitro. In contrast, B-cell lymphoma infiltrating to the bone marrow without bone destruction did not express RANKL. Both RANKL and VEGF were expressed by a portion of B-lymphoid cell lines, including Daudi and IM-9. These RANKL-expressing tumor cells enhanced osteoclastogenesis from RAW264.7 cells and human monocyte-derived preosteoclasts in the absence of stromal cells/osteoblasts in a RANKL-dependent manner. Furthermore, conditioned media from Daudi cells enhanced transmigration of preosteoclasts that was inhibited by anti-VEGF antibody, suggesting that tumor cell-derived VEGF mediates recruitment of osteoclast precursors. Moreover, cocultures of B-lymphoid cell lines with osteoclasts enhanced the growth of B-lymphoid cells. CONCLUSIONS: Some malignant B cells aberrantly express functional RANKL as well as VEGF to enhance osteoclastogenesis. The coexpression of RANKL and VEGF may also contribute to the close cellular interactions with osteoclastic cells, thereby forming a vicious cycle between osteoclastic bone destruction and tumor expansion in bone. 相似文献
32.
Results of a 36‐year surveillance program for ulcerative colitis‐associated neoplasia in the Japanese population 下载免费PDF全文
Junko Kishikawa Keisuke Hata Shinsuke Kazama Hiroyuki Anzai Takahide Shinagawa Koji Murono Manabu Kaneko Kazuhito Sasaki Koji Yasuda Kensuke Otani Takeshi Nishikawa Toshiaki Tanaka Tomomichi Kiyomatsu Kazushige Kawai Hiroaki Nozawa Soichiro Ishihara Teppei Morikawa Masashi Fukayama Toshiaki Watanabe 《Digestive endoscopy》2018,30(2):236-244
33.
34.
35.
Hironori Tsujimoto Hiroyuki Horiguchi Risa Takahata Satoshi Ono Yoshihisa Yaguchi Shinsuke Nomura Nozomi Ito Manabu Harada Hiromi Nagata Yusuke Ishibashi Keita Kouzu Satoshi Tsuchiya Yujiro Itazaki Seiichiro Fujishima Yoji Kishi Hideki Ueno 《Journal of gastroenterology and hepatology》2020,35(5):788-794
36.
37.
Tanaka S Nishigaki K Ojio S Okubo M Yasuda S Ishihara Y Kubota T Takasugi N Kawamura I Yamaki T Ushikoshi H Aoyama T Kawasaki M Takemura G Minatoguchi S 《Journal of cardiology》2008,52(1):39-48
BACKGROUND: Aspirin and anti-platelet drugs are used commonly for patients with coronary heart disease. Proton pump inhibitor (PPI) and high-dose H2-blocker were recommended for preventing NSAIDs-related ulcer. Previously H2-blocker reported to have some negative cardiovascular effects. Additionally, a recent in vitro study showed that PPI reduced cardiac contractility. In this study, we evaluated whether chronic administration of PPI and high-dose H2-blocker affects left ventricular function. METHOD: Fifty-two stable angina patients were enrolled and classified into PPI group ([P]; lansoprazole: 15mg/day, n=28), H2-blocker group ([H]; famotidine: 40mg/day, n=8), and control ([C]; none or mucosal-defense drug, n=16). Eligible patients showed normal cardiac function in initial catheterization without administrated PPI or H2-blocker. They received percutaneous coronary intervention and follow-up catheterization. We compared changes in ejection fraction (EF: %), end diastolic/systolic volume index (EDVI/ESVI: ml/m(2)), and peak positive/negative dp/dt (+/-dp/dt: mmHg/s) in left ventricular angiography series. RESULT: There were no significant differences among three groups regarding patient characteristics, backgrounds of angiographic and intervention, except for fewer smokers in [C]. Other drugs such as beta- and Ca-blocker did not have effects on cardiac function except for aspirin during 255+/-115 days follow-up. Rate of EF changes significantly decreased in [P], and tended to decrease in [H] (C: 3.8+/-9.8%, H: -1.6+/-7.6%, P: -2.1+/-5.9%; p<0.05 for [C] vs. [P]). Those of ESVI changes were significantly greater in [P], and tended to be greater in [H] (C: -4.5+/-16.2%, H: 4.9+/-15.5%, P: 7.3+/-16.2%; p<0.05 for [C] vs. [P]), though, EDVI changes' were similar (C: 2.5+/-8.9%, H: 2.6+/-3.6%, P: 1.6+/-6.1%; p=ns). Rate of +/-dp/dt-changes tended to decrease in [H] (+dp/dt: C: 3.9+/-15.5%, H: -10.0+/-25.2%, P: 0.3+/-19.6%; p=ns, -dp/dt: C: -0.1+/-19.5%, H: -8.5+/-20.4%, P: 5.7+/-27.7%; p=ns). CONCLUSION: In this study, PPI and high-dose H2-blocker have EF-reducing tendency. However, these changes were small and these drugs seemed to exhibit little influence clinically. 相似文献
38.
Neuromedin s is a novel anorexigenic hormone 总被引:4,自引:0,他引:4
Ida T Mori K Miyazato M Egi Y Abe S Nakahara K Nishihara M Kangawa K Murakami N 《Endocrinology》2005,146(10):4217-4223
A novel 36-amino acid neuropeptide, neuromedin S (NMS), has recently been identified in rat brain and has been shown to be an endogenous ligand for two orphan G protein-coupled receptors, FM-3/GPR66 and FM-4/TGR-1. These receptors have been identified as neuromedin U (NMU) receptor type 1 and type 2, respectively. In this study, the physiological role of the novel peptide, NMS, on feeding regulation was investigated. Intracerebroventricular (icv) injection of NMS decreased 12-h food intake during the dark period in rats. This anorexigenic effect was more potent and persistent than that observed with the same dose of NMU. Neuropeptide Y, ghrelin, and agouti-related protein-induced food intake was counteracted by coadministration of NMS. Icv administration of NMS increased proopiomelanocortin mRNA expression in the arcuate nucleus (Arc) and CRH mRNA in the paraventricular nucleus (PVN). Pretreatment with SHU9119 (antagonist for alpha-MSH) and alpha-helical corticotropin-releasing factor-(9-41) (antagonist for CRH) attenuated NMS-induced suppression of 24-h food intake. After icv injection of NMS, Fos-immunoreactive cells were detected in both the PVN and Arc. When neuronal multiple unit activity was recorded in the PVN before and after icv injection of NMS, a significant increase in firing rate was observed 5 min after administration, and this increase continued for 100 min. These results suggest that the novel peptide, NMS, may be a potent anorexigenic hormone in the hypothalamus, and that expression of proopiomelanocortin mRNA in the Arc and CRH mRNA in the PVN may be involved in NMS action on feeding. 相似文献
39.
40.